Anthera Pharmaceuticals Inc represents a strong commitment to advancing the treatment of patients with serious diseases. The company focuses on developing innovative therapies that target unmet medical needs. Blessed with a dedicated team of experts, Anthera Pharmaceuticals Inc aims to provide novel treatment options for conditions such as IgA nephropathy and lupus. Their corporate philosophy is rooted in scientific excellence, patient-centeredness, and collaboration with healthcare professionals and stakeholders. By combining cutting-edge research with clinical expertise, Anthera Pharmaceuticals Inc strives to make a meaningful impact on patients' lives and improve healthcare outcomes.

Anthera Pharmaceuticals Inc is primarily present in the United States of America.

Anthera Pharmaceuticals Inc has achieved several significant milestones in its history. One notable achievement was the successful completion of a Phase 3 clinical trial for their lead product candidate, blisibimod, in patients with systemic lupus erythematosus (SLE). This milestone demonstrated the potential efficacy and safety of blisibimod in treating SLE, a chronic autoimmune disease. Additionally, Anthera Pharmaceuticals Inc has received FDA Fast Track designation for blisibimod in IgA nephropathy, which highlights the importance and potential clinical value of their drug candidate. These milestones showcase the company's commitment to developing innovative therapeutics and advancing the treatment options for patients with serious diseases.

Anthera Pharmaceuticals Inc. is a biopharmaceutical company based in the United States. Founded in 2004, the company specializes in developing and commercializing innovative therapies for autoimmune diseases. Anthera Pharmaceuticals focuses on creating therapies that target specific elements of the immune system to provide improved outcomes for patients. Over the years, Anthera Pharmaceuticals has successfully advanced multiple drug candidates through clinical development stages. Their commitment to research and development has resulted in a robust pipeline of potential therapies for various autoimmune disorders. With a track record of innovation and a dedication to improving patient lives, Anthera Pharmaceuticals Inc. continues to contribute significantly to the field of biopharmaceuticals.

The main competitors of Anthera Pharmaceuticals Inc in the market are Amgen Inc, Gilead Sciences Inc, and Biogen Inc.

Anthera Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Anthera Pharmaceuticals Inc. focuses on developing and commercializing innovative therapeutics to address unmet medical needs. This biopharmaceutical company specializes in developing hormone-based treatments for serious and life-threatening diseases. Anthera Pharmaceuticals Inc. aims to improve patient outcomes and provide effective solutions for various conditions, including autoimmune diseases and cardiovascular disorders. Through extensive research and clinical trials, the company strives to bring novel therapies to the market that have the potential to make a significant impact on patient care and quality of life.

De K/W-verhouding kan momenteel niet worden berekend voor Anthera Pharmaceuticals.

De KUV kan momenteel niet worden berekend voor Anthera Pharmaceuticals.

De AlleAktien Kwaliteitsscore voor Anthera Pharmaceuticals is 5/10.

De omzet kan momenteel niet worden berekend voor Anthera Pharmaceuticals.

De winst kan momenteel niet berekend worden voor Anthera Pharmaceuticals.

Anthera Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medications for the treatment of serious diseases. The company covers various areas, such as autoimmune diseases, inflammations, and metabolic disorders. They have a wide range of products, particularly for autoimmune diseases like Lupus and acute heart attacks. One of their products, called 'Blisibimod', is a B-cell activating factor (BAFF) inhibitor currently in Phase III clinical trials for the treatment of Lupus. Another product in Phase II clinical trials is Sollpura, being developed for patients with chronic pancreatitis and exocrine pancreatic insufficiency (EPI) to aid in food digestion. Additionally, Anthera Pharmaceuticals is focused on developing medications for inflammation, including pneumonia. They have developed a medication called 'Gel-Pak' for pneumonia, currently in Phase II clinical trials. The company also pursues strategic alliances, such as its collaboration with Eli Lilly and Company for the development of autoimmune drugs. Their strategy is to focus on the development of medications that have the potential to change the standards of patient care. Anthera ensures that all their products undergo clinical testing and meet regulatory requirements. Currently, the company has no revenues from product sales and continues to rely on investors and partners for the development of their products. In summary, Anthera Pharmaceuticals focuses on the development of medications for the treatment of serious diseases. Through a wide range of products in various areas, the company seeks partnerships and investor collaborations to make their innovative therapies accessible to patients.

Anthera Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Anthera Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Anthera Pharmaceuticals is US03674U3005.

Het WKN van Anthera Pharmaceuticals is A2DMW5.

De ticker van Anthera Pharmaceuticals is ANTH.

Binnen de laatste 12 maanden betaalde Anthera Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Anthera Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Anthera Pharmaceuticals is momenteel .

Anthera Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Anthera Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Anthera Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Anthera Pharmaceuticals van 1-11-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 1-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-11-2024.

In het jaar 2023 heeft Anthera Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Anthera Pharmaceuticals worden in USD uitgekeerd.